Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics (IOVA)
NASDAQ:IOVA
IOVA Stock Chart & Stats
$2.61
-$0.33(-4.53%)
At close: 4:00 PM EST
$2.61
-$0.33(-4.53%)
Day’s Range― - ―
52-Week Range$1.64 - $6.50
Previous CloseN/A
Volume2.95M
Average Volume (3M)10.67M
Market Cap
$1.04B
Enterprise Value$541.65M
Total Cash (Recent Filing)$300.80M
Total Debt (Recent Filing)$52.49M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Mar 03, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding396,967,960
10 Day Avg. Volume9,977,178
30 Day Avg. Volume10,665,984
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)3.02
Price to Sales (P/S)13.07
P/FCF Ratio-5.89
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue2.16
Enterprise Value/Gross Profit5.58
Enterprise Value/Ebitda-1.47
Forecast
1Y Price Target
$9.50Price Target Upside263.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Validation And Label ExpansionPositive nonsquamous NSCLC data validate the tumor-infiltrating lymphocyte (TIL) strategy and strengthen the case for lifileucel to extend commercially beyond melanoma.
Profitability And Gross MarginsOperational efficiencies and cost-saving measures have improved gross margins, supporting a clearer path toward sustained profitability as AMTAGVI uptake increases.
Regulatory ApprovalsHealth Canada approval for AMTAGVI combined with expected approvals in the United Kingdom and Australia in the first half of 2026 and a pathway in Switzerland expands addressable markets and supports future commercial growth.
Bears Say
Credibility And Guidance RiskMissed financial targets and subsequent estimate cuts have eroded management credibility, making the restoration of investor trust a material execution risk.
Investor Sentiment PressurePersistent negative investor sentiment has placed the stock in a valuation 'penalty box', which can limit recovery even when company developments are positive.
Share Momentum And Technical WeaknessEarly intraday gains faded and the stock trading below short-term moving averages signals weak momentum and may discourage momentum-focused investors.
Iovance Biotherapeutics News
IOVA FAQ
What was Iovance Biotherapeutics’s price range in the past 12 months?
Iovance Biotherapeutics lowest stock price was $1.64 and its highest was $6.50 in the past 12 months.
What is Iovance Biotherapeutics’s market cap?
Iovance Biotherapeutics’s market cap is $1.04B.
When is Iovance Biotherapeutics’s upcoming earnings report date?
Iovance Biotherapeutics’s upcoming earnings report date is Mar 03, 2026 which is in 49 days.
How were Iovance Biotherapeutics’s earnings last quarter?
Iovance Biotherapeutics released its earnings results on Nov 06, 2025. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.258 by $0.008.
Is Iovance Biotherapeutics overvalued?
According to Wall Street analysts Iovance Biotherapeutics’s price is currently Undervalued.
Does Iovance Biotherapeutics pay dividends?
Iovance Biotherapeutics does not currently pay dividends.
What is Iovance Biotherapeutics’s EPS estimate?
Iovance Biotherapeutics’s EPS estimate is -0.17.
How many shares outstanding does Iovance Biotherapeutics have?
Iovance Biotherapeutics has 396,967,960 shares outstanding.
What happened to Iovance Biotherapeutics’s price movement after its last earnings report?
Iovance Biotherapeutics reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.258. Following the earnings report the stock price went up 27.624%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics?
Currently, no hedge funds are holding shares in IOVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iovance Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.50 (263.98% Upside)
$9.50 (263.98% Upside)
Blogger Sentiment
Bullish
IOVA Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-63.59%
12-Months-Change
Fundamentals
Return on Equity
-53.89%
Trailing 12-Months
Asset Growth
-8.69%
Trailing 12-Months
Company Description
Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
IOVA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, highlighting significant revenue growth, successful strategic restructuring, and promising clinical data in lung cancer. However, challenges remain in expense management, global market expansion, and community ATC adoption.View all IOVA earnings summariesIOVA Stock 12 Month Forecast
Average Price Target
$9.50
▲(263.98% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Vir Biotechnology
―
Immatics
―
Nuvation Bio
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
0.30% Insiders
11.01% Mutual Funds
0.02% Other Institutional Investors
73.70% Public Companies and Individual Investors